Angel Comulada Rivera
Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1669559803
Payments from drug & device makers
Across 1,203 payments — averaging $7365.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$4.4M
- Eli Lilly$3M
- Boehringer Ingelheim$878K
- Novartis$300K
- Alnylam Pharmaceuticals Inc.$160K
- Novo Nordisk AS$89K
- plus $37K from 13 others
Across 41 payments — averaging $5685.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$212K
- Eli Lilly Export S.A. Puerto Rico Branch$19K
- AbbVie$1K
- Novo Nordisk AS$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 32 | $4,440,274 |
| Eli Lilly | 207 | $2,956,492 |
| Boehringer Ingelheim | 20 | $877,608 |
| Novartis | 13 | $300,113 |
| Alnylam Pharmaceuticals Inc. | 189 | $159,555 |
| Novo Nordisk AS | 591 | $89,260 |
| Boehringer Ingelheim International GmbH | 86 | $22,373 |
| AbbVie | 3 | $10,154 |
| Medtronic(2 entities) | 9 | $2,096 |
| Sanofi-aventis U.S. LLC | 12 | $928 |
| Johnson & Johnson | 11 | $699 |
| Dexcom, Inc. | 6 | $370 |
| Merck | 7 | $261 |
| AstraZeneca | 7 | $109 |
| Lilly USA, LLC | 1 | $100 |
| Novo Nordisk | 4 | $74 |
| PBG Puerto Rico LLC | 2 | $42 |
| Abbott | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
How this compares
$8,860,564 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Bayamon
- Paola Mansilla-LetelierBayamon$3.1M
- Altagracia Alcantara GonzalezBayamon$1M
- Jean Pujals KuryBayamon$50K
- Gloria Vega CarattiniBayamon$26K
- Hiram Maldonado RiveraBayamon$7K
- Ramon Ortiz CarrasquilloManati$6M
- Alex Gonzalez BossoloSan Juan$5.5M
- Martha GomezSan Juan$3.8M
- Myriam Allende-VigoHumacao$963K
- Jose Garcia MateoPonce$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.